Skip to main content
. 2021 Jun 23;19:189. doi: 10.1186/s12951-021-00935-z

Fig. 6.

Fig. 6

Anticancer activity of FeSiNTs/siSPAG5 in a T24 in-situ bladder cancer mouse model. A Representative excised bladders and H&E stained tissue slices (muscle invasive bladder cancer: ≥ stage pT2) treated with PBS. B Representative excised bladders and H&E stained tissue slices (muscle invasive bladder cancer: ≥ stage pT2) treated with siSPAG5. C Representative excised bladders and H&E stained tissue slices (muscle invasive bladder cancer: ≥ stage pT2) treated with FeSiNTs. D Representative excised bladders and H&E stained tissue slices (noninvasive papillary carcinoma: stage pTa) treated with FeSiNTs/siSPAG5